4.8 Article

TGF-beta 1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 120, 期 1, 页码 290-302

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI39194

关键词

-

资金

  1. NIH [R01 CA 109262, 5U19Al067773-04]
  2. Department of Energy [DE-FG02-09ER64789]
  3. Immunohistochemistry and Biological Microscopy Cores at the Simon Cancer Center, Indiana University [NIH P30CA08709]
  4. Biostatistics Core, Simmons Comprehensive Cancer Center, University of Texas Southwestern [NIH P30CA142543]
  5. NATIONAL CANCER INSTITUTE [R01CA109262, P30CA142543, R01CA102792, R01CA139217] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067773] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The E3 ubiquitin ligase human murine double minute (HDM2) is overexpressed in 40%-80% of late-stage metastatic cancers in the absence of gene amplification. Hdm2 regulates p53 stability via ubiquitination and has also been implicated in altering the sensitivity of cells to TGF-beta 1. Whether TGF-beta 1 signaling induces Hdm2 expression leading to HDM2-mediated destabilization of p53 has not been investigated. In this study, we report that TGF-beta 1-activated SMA- and MAD3 (Smad3/4) transcription factors specifically bound to the second promoter region of HDM2, leading to increased HDM2 protein expression and destabilization of p53 in human cancer cell lines. Additionally, TGF-beta 1 expression led to Smad3 activation and murine double minute 2 (Mdm2) expression in murine mammary epithethial cells during epithelial-to-mesenchymal transition (EMT). Furthermore, histological analyses of human breast cancer samples demonstrated that approximately 65% of late-stage carcinomas were positive for activated Smad3 and HDM2, indicating a strong correlation between TGF-beta 1-mediated induction of HDM2 and late-stage tumor progression. Identification of Hdm2 as a downstream target of TGF-beta 1 represents a critical prosurvival mechanism in cancer progression and provides another point for therapeutic mtervention in late-stage cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据